In women, obesity has been implicated further in menstrual  disorders, infertility, and adverse pregnancy outcomes. Obese women have been  reported to suffer more often from irregular cycles and anovulation than lean  women. They not only have a higher risk of suffering from infertility, but also  face complications resulting from infertility treatments. Once they do achieve  pregnancy, obese women demonstrate higher rates of miscarriage, gestational  diabetes, and hypertensive pregnancy disorders as well as birth complications  and cesarean sections.
    Therefore, the increased prevalence of obesity has important  implications for gynecologists and obstetricians. The most obvious solution  (weight loss) is extremely hard to achieve for most patients. Moreover, studies  evaluating the effect of weight reduction on fertility and pregnancy outcomes  report conflicting results. Particularly regarding fertility, some  investigators have described a reduction in the time to pregnancy after weight  reduction, while others have not found any beneficial effect.
    Therefore, it is extremely important to elucidate the  underlying pathophysiology responsible for the association between high body  mass index and impaired reproductive function. Many previous studies have  concentrated on obese women with polycystic ovary syndrome (PCOS), but this  population represents only a subgroup of obese women in which the two  conditions may be confounding. 
    In studies evaluating the metabolic and endocrine profile of  obese women, the coexistence of decreased FSH and LH secretion with  hyperlipidemia and hyperinsulinemia has been observed. Therefore, the term ''reprometabolic  syndrome'' has been coined by Santoro et al. to characterize this condition and  emphasize the profound impact of obesity on female reproductive function. 
    To better elucidate this correlation, Santoro et al.  published a previous study in 2017, in which they aimed to reproduce the  metabolic changes typically observed in obese patients – more precisely,  hyperlipidemia combined with hyperinsulinemia – in lean regularly cycling women  and in lean men. Using a crossover study design, they administered infusions of  saline (control), lipid solution alone, insulin alone (while maintaining  euglycemia), and the combination of lipid solution and insulin over 6 hours,  respectively, in a random order over four separate study visits. They measured  LH and FSH twice-hourly and found these to be significantly decreased in women  and men after the combined lipid and insulin solution compared to  saline-control. In contrast, neither lipid nor insulin alone led to significant  changes in gonadotropin levels. The investigators concluded that  hyperinsulinemia combined with elevated lipid levels suppresses gonadotropin  secretion in the short term and hypothesized that this might be the  pathophysiologic mechanism underlying hypogonadotropic hypogonadism in obese  women.
    In an article published in Fertility and Sterility, Santoro  et al. report the results of a subsequent and expanded study, again using a  randomized crossover design, evaluating the short term induction of the  reprometabolic syndrome in lean women. Accounting for their previous results,  they compared only two scenarios: infusion of lipid plus insulin vs. infusion  of saline-control. The study included eumenorrheic, normal-weight women who  underwent one 6-hour infusion with each of these two solutions in a random order.  Blood sampling was performed every 10 minutes, to better characterize the time  course of gonadotropin secretion and examine secretion patterns in response to  the two interventions. Consequently, the investigators were able to analyze LH  pulse amplitude and frequency in addition to mean FSH and LH levels, as  reported previously in their earlier study. 
    They found a reduced LH pulse amplitude after infusion of  lipid plus insulin (mean pulse amplitude 1.49 IU/L) compared to saline infusion  (2.33 IU/L, P ¼ .14). LH pulse frequency did not differ significantly. In  addition, as obese women have been reported to show a reduced responsiveness to  exogenous gonadotropin releasing hormone (GnRH), this study further examined  the LH response to an exogenous GnRH bolus. LH response was reduced  significantly after infusion of lipid plus insulin (P ¼ .02), when one  participant with very high LH and antimullerian levels was excluded, indicating  a reduced pituitary sensitivity because of the metabolic changes induced.
    The investigators showed decreased LH pulse amplitude and a reduced  response to GnRH induced by hyperinsulinemia combined with hyperlipidemia,  implicating a pituitary origin of the low gonadotropin levels. It is  striking how rapidly the endocrine effects of a short term administration of  insulin and lipid infusion appeared in the lean women included in this study. This  indirectly implies that specific and reversible dietary factors, especially  those foods with a high glycemic index which rapidly raise glucose and insulin,  may have a significant role for the reprometabolic syndrome. If this is indeed  true, then the consistency of one's diet is of critical importance and could be  explored as a potential target for the development of new therapeutic  strategies.
    "Future studies should investigate whether an improvement of  insulin and lipid levels really leads to an improvement of the reproductive  outcomes of obese women, to confirm the causal relationship of these metabolic  changes with infertility. In the meantime, when counseling obese patients  wishing to conceive, we clinicians should keep in mind that a modification of  the consistency of the diet and lifestyle might be more important than the  number of kilograms lost."
    Source: https://doi.org/10.1016/j.fertnstert.2021.06.002
 
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.